Amyloid-beta: The Alternate Hypothesis

β 淀粉样蛋白：替代假设

• 批准号: 6927663
• 负责人: MARK A SMITH
• 金额: $ 25.34万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-01 至 2008-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6927663
• 关键词: Alzheimer' s disease; aging; amyloid proteins; antioxidants; cytotoxicity; enzyme linked immunosorbent assay; intracellular; neuroprotectants; oxidation reduction reaction; oxidative stress; pathologic process; small interfering RNA; tissue /cell culture; western blottings

DESCRIPTION (provided by applicant): The "Amyloid Cascade Hypothesis" positing amyloid-ft (Aft) as a fundamental driving mechanism in disease pathogenesis is supported by numerous cellular, animal and human studies. However, an "Alternate Amyloid Hypothesis", positing Aft as an antioxidant that occurs secondary to oxidative stress, is an equally valid explanation for the wealth of in vitro and in vivo findings related to Aft. That the "Alternate Amyloid Hypothesis" and the "Amyloid Cascade Hypothesis" are essentially unchallenged by any currently available data is troubling from a scientific perspective and more so from a clinical perspective where current therapeutic efforts are targeted at the removal or limiting of Aft from the brain. The goal of our proposal is to conduct a series of experiments that should critically test both hypotheses to determine the role of Aft as pathogen or protectant. Specifically, we propose to use inducible transfected cell cultures together with state of the art molecular techniques to test the predominant hypothesis in the field. Our Specific Aims, guided by novel preliminary data are as follows: Aim 1) Determine whether pharmacologic inhibition of Aft with BACE inhibitors affects susceptibility to oxidative stress and whether this effect can be reversed ("rescued") by transfection with Aft1-40, Aft1-42, or C99; Aim 2) Determine whether mutations associated with familial Alzheimer disease are associated with alterations in oxidative stress and whether alterations in Aft production are affected by antioxidants or, vice versa, whether oxidative stress is altered by inhibition of Aft; Aim 3) Determine whether Aft is regulated by intracellular redox balance. Completion of the proposed studies will help determine the role of Aft and, more importantly, guide future therapeutic targets.

描述（由申请人提供）：许多细胞、动物和人体研究支持“淀粉样蛋白级联假说”，该假说将淀粉样蛋白-ft（Aft）定位为疾病发病机制中的基本驱动机制。然而，“替代淀粉样蛋白假说”，假定Aft作为一种抗氧化剂，发生继发于氧化应激，是一个同样有效的解释丰富的体外和体内的研究结果有关的Aft。“替代淀粉样蛋白假说”和“淀粉样蛋白级联假说”基本上没有受到任何当前可用数据的挑战，这从科学的角度来看是令人不安的，从临床的角度来看更是如此，其中当前的治疗努力旨在从大脑中去除或限制Aft。我们提案的目标是进行一系列实验，严格检验这两种假设，以确定Aft作为病原体或保护剂的作用。具体而言，我们建议使用诱导型转染细胞培养物以及最先进的分子技术来测试该领域的主要假设。在新的初步数据的指导下，我们的具体目标如下：目的1）确定BACE抑制剂对Aft的药理学抑制是否影响对氧化应激的易感性，以及这种作用是否可以逆转（“拯救的”）通过用Aft 1 -40、Aft 1 -42或C99转染;目标2）确定与家族性阿尔茨海默病相关的突变是否与氧化应激的改变有关，以及Aft产生的改变是否与阿尔茨海默病相关。受抗氧化剂影响，或反之亦然，氧化应激是否通过抑制Aft而改变;目的3）确定Aft是否受细胞内氧化还原平衡调节。完成拟议的研究将有助于确定Aft的作用，更重要的是，指导未来的治疗目标。